We report two patients whose thyrotoxicosis failed to respond to conventional treatment with carbimazole. The patients remained persistently hyperthyroid, both clinically and biochemically, despite several months of carbimazole therapy at the maximum recommended doses. Prednisolone 20 mg per day was then given in addition to the antithyroid drug and a dramatic reponse observed in both cases. They were then successfully treated with radioiodine.
Summary
We report two patients whose thyrotoxicosis failed to respond to conventional treatment with carbimazole. The patients remained persistently hyperthyroid, both clinically and biochemically, despite several months of carbimazole therapy at the maximum recommended doses. Prednisolone 20 mg per day was then given in addition to the antithyroid drug and a dramatic reponse observed in both cases. They were then successfully treated with radioiodine.
Prednisolone has not been previously used to treat patients with hyperthyroidism who have not responded to thionamide drugs. Our experience suggests that corticosteroids may be potentially useful for controlling thyrotoxicosis in combination with carbimazole before definite treatment can be instituted.
Keywords: thyrotoxicosis, prednisolone, carbimazole resistance Thionamides have been used in the treatment of hyperthyroidism for over 50 years. Most patients respond within four to six weeks of initiating treatment and the dose is reduced to a maintenance level for a further six to 12 months. Rarely, patients are found not to respond to antithyroid drugs (carbimazole or propylthiouracil) and this poses a difficult management problem. Such patients are usually thought to have failed to comply with their medication.
Corticosteroids are often used in the management of thyroid crisis.' However, they have not been recognised as useful therapy in the management of patients not responding to antithyroid drugs alone. We report two patients who remained persistently thyrotoxic despite treatment with carbimazole at the recommended dose for four months.
Case 1 A 30-year-old woman had had symptoms of thyrotoxicosis with palpitations, mood changes, heat intolerance, weight loss and diarrhoea for six months. On examination she was lean (body mass index 19), and had sinus tachycardia with a heart rate of 120 beats/min. She had a diffuse goitre with a bruit and fine tremor of her hands, but no eye signs apart from lid lag. Thyroid function tests confirmed hyperthyroidism with free thyroxine of 37 pmol/l (normal 1-24 pmolIl), free triiodothyronine of 12.7 pmolIl (4.2-7.1 pmolIl) and thyroid stimulating hormone of 0.2 mU/l (0.3-3.8 mU/l). Thyroid antimicrosomal and antithyroglobulin antibody titres were 1:400 and negative, respectively. She was treated with carbimazole 30 mg daily but two months later she was still clinically thyrotoxic and her free thyroxine was 41.6 pmol/l. The carbimazole was increased to 60 mg daily. She was also prescribed propranolol but it had to be discontinued owing to respiratory wheeze. Four months later, on the maximum recommended dose of carbimazole, she felt no better and her free thyroxine was 46 pmol/l. Noncompliance with the prescribed medication was suspected, but on repeated questioning she asserted that she was taking her treatment regularly. She was then started on prednisolone 20 mg daily in addition to the carbimazole. There was marked improvement in her symptoms within four weeks and she was clinically euthyroid, which was confirmed with a free thyroxine of 28.8 pmol/l. At this stage she was given radioactive iodine 400 MBq. Two months later her free thyroxine was 17.7 pmol/l (figure). The carbimazole was then stopped and prednisolone was gradually withdrawn; 15 months hence she is euthyroid and clinically well.
Case 2 A 46-year-old woman presented with symptoms of tremors, weight loss, tiredness, increased sweating, irritability and inability to concentrate at work. On examination she had a The latter is a syndrome complex due to the action on the thyroid of IgG immunoglobulins that may be antibodies against components or regions of the thyroid plasma membrane, possibly regions that include the receptor for thyroid stimulating hormone itself. Thus, the reason why patients respond to corticosteroids could be two-fold. The more immediate effect could be the inhibition of conversion of thyroxine to triiodothyronine in the peripheral tissue,5 blocking the release of thyroxine from the thyroid. It may also lead to suppression of the immune response and hence decreased stimulation of the thyroid gland by the altered immune response and cell-mediated immunity. Clearly, further studies are needed to examine the effect of such immunosuppressive therapy in Graves' disease.
Our experience suggests that there are some patients who may benefit from the use of corticosteroids as an adjunct to antithyroid drugs in the treatmnent of Graves' disease. Such patients would include those in whom the response to carbimazole has been poor and also those patients in whom rapid remission of the disease is required, such as in the elderly and in patients with thyrotoxic heart disease. These cases demonstrate the potential value of prednisolone in rapid control of thyrotoxicosis, where a decision has been made to proceed with definitive treatment such as surgery or radioiodine.
5 Chopra IJ, Williams DE, Orgiazzi J, Solomon DH. Opposite effects of dexamethazone on serum concentrations of 3,3',5'-triiodothyronine (reverse T3) and 3,3',5'-triiodothyronine (T3 Laxatives account for a significant proportion of over-the-counter (OTC) pharmacy sales (C37m in 1994 out of a total of £1268m OTC pharmacy and grocery sales). The wide variety and easy availability can lead to excessive use, inappropriate dosage, and even abuse of these medicines. Loss of fluid and electrolytes in diarrhoea may result in secondary hyperaldosteronism and hypokalaemia. Oedema may be a feature of the recovery phase after laxative withdrawal.
We describe a patient whose excessive laxative intake led to life-threatening cardiac failure after the laxatives were withdrawn.
Case report
A 60-year-old woman underwent a bilateral salpingo-oophorectomy for endometrial carcinoma in December 1987. She made a good recovery and routine follow-up showed no evidence of recurrence. Following the operation, she was told to avoid straining at stool and was prescribed Fybogel sachets and senna tablets. She felt this laxative regimen did not have the desired effect and some months later, on the advice of a friend, she started to take Fam-Lax (phenolphthalein and rhubarb) which she bought over-the-counter. Starting with the recommended adult dose of two tablets, she soon increased this to five tablets per day. This produced a liquid, easily passed stool within a few hours.
Whilst on holiday in Spain in 1993 she felt weak and exhausted and was told she had a low blood pressure. By the time of her return home the symptoms had become more severe and eventually resulted in her admission to hospital.
On admission, her blood pressure was 105/ 60 mmHg. Clinically her heart was normal and there was no evidence of cardiac failure. Urea and electrolytes were within the normal range except for serum potassium which was found to be low at 2.6 mmol/l. Her prescribed medication consisted of medroxyprogesterone, sucralfate, ranitidine and co-dydramol.
In the absence of any other obvious cause for her hypokalaemia, laxative abuse was suspected. She admitted to taking the Fam-Lax -she had simply been following instructions not to strain at stool.
The laxatives were withdrawn and oral potassium supplements started (Sando-K 2 bid). Serum potassium rose rapidly to normal levels over the next four days (figure). 
